Spin-Flipping Half Vortex in a Macroscopic Polariton Spinor Ring Condensate

We report the observation of vorticity in a macroscopic Bose-Einstein condensate of polaritons in a ring geometry. Because it is a spinor condensate, the elementary excitations are "half vortices" in which there is a phase rotation of $\pi$ in connection with a polarization vector rotation of $\pi$ around a closed path. This is clearly seen in the experimental observations of the polarization rotation around the ring. In the ring geometry, a new type of half vortex is allowed in which the handedness of the spin flips from one side of the ring to the other, in addition to the rotation of the linear polarization component; such a state is not allowed in a simply-connected geometry. Theoretical calculation of the energy of this state shows that when many-body interactions are taken into account, it is lower in energy than a simple half vortex. The direction of circulation of the flow around the ring fluctuates randomly between clockwise and counterclockwise from one shot to the next; this corresponds to spontaneous breaking of time-reversal symmetry in the system. These new, macroscopic polariton ring condensates allow for the possibility of direct control of the vorticity of the condensate.Comment: 21 pages, 10 figures, including supplemental information; Proceedings of the National Academy of Sciences (USA) (2015

Subtractive CRISPR screen identifies the ATG16L1/vacuolar ATPase axis as required for non-canonical LC3 lipidation

Although commonly associated with autophagosomes, LC3 can also be recruited to membranes by covalent lipidation in a variety of non-canonical contexts. These include responses to ionophores such as the M2 proton channel of influenza A virus. We report a subtractive CRISPR screen that identifies factors required for non-canonical LC3 lipidation. As well as the enzyme complexes directly responsible for LC3 lipidation in all contexts, we show the RALGAP complex is important for M2-induced, but not ionophore drug-induced, LC3 lipidation. In contrast, ATG4D is responsible for LC3 recycling in M2-induced and basal LC3 lipidation. Identification of a vacuolar ATPase subunit in the screen suggests a common mechanism for non-canonical LC3 recruitment. Influenza-induced and ionophore drug-induced LC3 lipidation lead to association of the vacuolar ATPase and ATG16L1 and can be antagonized by Salmonella SopF. LC3 recruitment to erroneously neutral compartments may therefore represent a response to damage caused by diverse invasive pathogens

Evaluation of Visible Diffuse Reflectance Spectroscopy in Liver Tissue: Validation of Tissue Saturations Using Extracorporeal Circulation

Significance: Real-time information about oxygen delivery to the hepatic graft is important to direct care and diagnose vascular compromise in the immediate post-transplant period. Aim: The current study was designed to determine the utility of visible diffuse reflectance spectroscopy (vis-DRS) for measuring liver tissue saturation in vivo. Approach: A custom-built vis-DRS probe was calibrated using phantoms with hemoglobin (Hb) and polystyrene microspheres. Ex vivo (extracorporeal circulation) and in vivo protocols were used in a swine model (n=15) with validation via blood gas analysis. Results: In vivo absorption and scattering measured by vis-DRS with and without biliverdin correction correlated closely between analyses. Lin’s concordance correlation coefficients are 0.991 for μa and 0.959 for μs\u27. Hb measured by blood test and vis-DRS with (R2=0.81) and without (R2=0.85) biliverdin correction were compared. Vis-DRS data obtained from the ex vivo protocol plotted against the PO2 derived from blood gas analysis showed a good fit for a Hill coefficient of 1.67 and P50=34  mmHg (R2=0.81). A conversion formula was developed to account for the systematic deviation, which resulted in a goodness-of-fit (R2=0.76) with the expected oxygen dissociation curve. Conclusions: We show that vis-DRS allows for real-time measurement of liver tissue saturation, an indicator for liver perfusion and oxygen delivery

Chemical Reaction Dynamics at Surfaces

Contains reports on two research projects with publication lists in each section.Joint Services Electronics Program Contract DAAL03-89-C-0001MIT Energy Laboratory Synthetic Fuels CenterNational Science Foundation Grant CHE 85-08734Petroleum Research Fund Contract 19014-AC

Evaporative dense water formation and cross-shelf exchange over the northwest Australian inner shelf

Author Posting. © American Geophysical Union, 2010. This article is posted here by permission of American Geophysical Union for personal use, not for redistribution. The definitive version was published in Journal of Geophysical Research 115 (2010): C06027, doi:10.1029/2009JC005931.High-resolution surveys of oceanographic and atmospheric conditions made during the winter over the inner shelf off northwest Australia are used to examine the coastal ocean response to large outgoing heat and freshwater fluxes. Relatively cool, low-humidity air blows off the Australian continent out over the tropical continental shelf, resulting in a large mean latent heat flux (−177 W m−2) that overwhelms insolation and, along with the outgoing long-wave radiation, results in substantial net cooling (−105 W m−2) and evaporative freshwater flux (0.6 cm d−1). The inner shelf is characterized by increasingly cool, salty, and dense waters onshore, with a strong front near the 25 m isobath. The front is evident in satellite sea surface temperature (SST) imagery along the majority of the northwest Australian shelf, exhibiting a complex filamentary and eddy structure. Cross-shelf buoyancy fluxes estimated from the mean, two-dimensional heat and salt budgets are comparable to parameterizations of cross-shelf eddy driven fluxes; however, the same fluxes can be achieved by cross-shelf transports in the bottom boundary layer of about 0.5 m2 s−1 (and an overlying return flow).The Office of Naval Research funded this effort (grant N00014‐00‐10767)

Development of Drugs for Nontuberculous Mycobacterial Disease:Clinicians’ Interpretation of a US Food and Drug Administration Workshop

The US Food and Drug Administration convened a workshop to discuss clinical trial design challenges and considerations related to the treatment of nontuberculous mycobacterial pulmonary disease, to include topics such as clinical trial end points, duration, and populations. The clinicians participating in the meeting provide here their interpretation of the discussion, which included US Food and Drug Administration and industry representatives. The treatment of nontuberculous mycobacterial pulmonary disease typically includes multiple antibiotics for a prolonged period and can be difficult to tolerate; there is a great need for new treatment options. Most individuals have a microbiologic response to therapy, but data correlating decreasing bacillary load with patient-reported outcomes or measured functional improvement are lacking. Accordingly, trial designs for new therapeutic agents should incorporate both microbiologic and clinical outcome measures and select appropriate study candidates with capacity for measurable change of such outcome measures. The need for shorter study designs, early primary end points, and placebo control arms was highlighted during the workshop

Rationale and Methods for the National Tuberculosis Genotyping and Surveillance Network

Our understanding of tuberculosis (TB) transmission dynamics has been refined by genotyping of Mycobacterium tuberculosis strains. The National Tuberculosis Genotyping and Surveillance Network was designed and implemented to systematically evaluate the role of genotyping technology in improving TB prevention and control activities. Genotyping proved a useful adjunct to investigations of outbreaks, unusual clusters, and laboratory cross-contamination

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with preexisting inflammatory lung disease such as cystic fibrosis(CF). Pulmonary disease caused by NTM has emerged as a major threat to the health of individuals with CF but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened an expert panel of specialists to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM pulmonary disease in individuals with CF. Nineteen experts were invited to participate in the recommendation development process. Population, Intervention, Comparison, Outcome (PICO) methodology and systematic literature reviews were employed to inform draft recommendations. An anonymous voting process was used by the committee to reach consensus. All committee members were asked to rate each statement on a scale of: 0, completely disagree, to 9, completely agree; with 80% or more of scores between 7 and 9 being considered ‘good’ agreement. Additionally, the committee solicited feedback from the CF communities in the USA and Europe and considered the feedback in the development of the final recommendation statements. Three rounds of voting were conducted to achieve 80% consensus for each recommendation statement. Through this process, we have generated a series of pragmatic, evidence-based recommendations for the screening, investigation, diagnosis and treatment of NTM infection in individuals with CF as an initial step in optimising management for this challenging condition

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement

Nontuberculous mycobacterial pulmonary diseases (NTM-PD) are increasingly recognised as opportunistic infections of humans. These chronic pulmonary infections have two main presentations. The first is a fibro-cavitary disease, that occurs in patients with pre-existing pulmonary diseases, such as chronic obstructive pulmonary disease, bronchiectasis, previous tuberculosis or other structural lung disease. The second presentation is a nodular- bronchiectatic disease of primarily the lingula and middle lobe that tends to affect a middle- aged and elderly female population [1]. Treatment of NTM-PD requires long-term administration of complex multidrug therapies that are species-specific. Currently recommended regimens are supported by a very limited evidence base [2, 3]. The increasing incidence of NTM-PD has sparked increased interest in performing prospective randomised clinical trials [4]. One of the drawbacks of the existing case series and clinical trials is that they have applied different outcome measures [5]. This hampers meta-analyses, which are important in these still understudied infectious diseases. To enhance the quality and interpretability of the results of future trials and retrospective cohort studies, we aimed to formulate clear and broadly acceptable outcome definitions for NTM-PD treatment